関: ultralente insulin

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/06/05 16:25:34」(JST)

wiki en

'Ultralente insulin is a long acting form of insulin. It has an onset of 4 to 6 hours, a peak of 14 to 24 hours, and a duration of 28 to 36 hours.^[1] This, along with lente form of insulin, was discontinued in the US by Eli Lilly and Company in 2005. One of the reasons for discontinuation was declining use due to physicians favoring NPH insulin and other basal insulin drugs.^[2]

References

^ Gomella LG, Haist SA. Chapter 22. Commonly Used Medications. In: Gomella LG, Haist SA, eds. Clinician's Pocket Reference: The Scut Monkey. 11th ed. New York: McGraw-Hill; 2007. http://www.accessmedicine.com/content.aspx?aID=2696124. Accessed February 4, 2012
^ http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/ucm086084.pdf

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 2型糖尿病におけるインスリン療法 insulin therapy in type 2 diabetes mellitus
2. 糖尿病におけるインスリン療法の一般原則 general principles of insulin therapy in diabetes mellitus
3. 成人の1型糖尿病におけるインスリン療法 insulin therapy in adults with type 1 diabetes mellitus
4. 小児および思春期における1型糖尿病のマネージメント management of type 1 diabetes mellitus in children and adolescents
5. 2型糖尿病における持続性高血糖のマネージメント management of persistent hyperglycemia in type 2 diabetes mellitus

English Journal

Are bedtime nutritional strategies effective in preventing nocturnal hypoglycaemia in patients with type 1 diabetes?

Desjardins K1, Brazeau AS, Strychar I, Rabasa-Lhoret R.
Diabetes, obesity & metabolism.Diabetes Obes Metab.2014 Jul;16(7):577-87. doi: 10.1111/dom.12232. Epub 2013 Dec 9.
Hypoglycaemia remains the major limiting factor for adequate diabetes control for patients with type 1 diabetes (T1D), especially during the night-time. Although nutritional strategies for nocturnal hypoglycaemia (NH) prevention are regularly suggested in clinical practice, there is no evidence-base
PMID 24320159

High-resolution powder X-ray data reveal the T(6) hexameric form of bovine insulin.

Margiolaki I1, Giannopoulou AE, Wright JP, Knight L, Norrman M, Schluckebier G, Fitch AN, Von Dreele RB.
Acta crystallographica. Section D, Biological crystallography.Acta Crystallogr D Biol Crystallogr.2013 Jun;69(Pt 6):978-90. doi: 10.1107/S0907444913003867. Epub 2013 May 11.
A series of bovine insulin samples were obtained as 14 polycrystalline precipitates at room temperature in the pH range 5.0-7.6. High-resolution powder X-ray diffraction data were collected to reveal the T6 hexameric insulin form. Sample homogeneity and reproducibility were verified by additional sy
PMID 23695242

Effects of local insulin delivery on subperiosteal angiogenesis and mineralized tissue formation during fracture healing.

Paglia DN1, Wey A, Breitbart EA, Faiwiszewski J, Mehta SK, Al-Zube L, Vaidya S, Cottrell JA, Graves D, Benevenia J, O'Connor JP, Lin SS.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society.J Orthop Res.2013 May;31(5):783-91. doi: 10.1002/jor.22288. Epub 2012 Dec 13.
Local insulin delivery has been shown to improve osseous healing in diabetic animals. The purpose of this study was to quantify the effects of local intramedullary delivery of saline or Ultralente insulin (UL) on various fracture healing parameters using an in vivo non-diabetic BB Wistar rat model.
PMID 23238777

Japanese Journal

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin insulin analog Glargin, NPH insulin, and ultralente human insulin and continuous subcutaneous insulin of insulin Lispro

LEPORE Mauro
Diabetes 49, 2142-2148, 2000
NAID 30026270249

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro

LEPORE M
Diabetes 49, 2142-2148, 2000
NAID 10010229755

Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen